Read by QxMD icon Read

Aspirin colorectal cancer

Yan Qiao, Tingting Yang, Yong Gan, Wenzhen Li, Chao Wang, Yanhong Gong, Zuxun Lu
BACKGROUND: Epidemiological studies have clarified the potential associations between regular aspirin use and cancers. However, it remains controversial on whether aspirin use decreases the risk of cancers risks. Therefore, we conducted an updated meta-analysis to assess the associations between aspirin use and cancers. METHODS: The PubMed, Embase, and Web of Science databases were systematically searched up to March 2017 to identify relevant studies. Relative risks (RRs) with 95% confidence intervals (CIs) were used to assess the strength of associations...
March 13, 2018: BMC Cancer
Xiaohong Ruby Xu, George M Yousef, Heyu Ni
Platelets have long been recognized as key players in hemostasis and thrombosis; however, growing evidence suggests that they are also significantly involved in cancer, the second leading cause of mortality worldwide. Preclinical and clinical studies showed that tumorigenesis and metastasis can be promoted by platelets through a wide variety of crosstalk between platelets and cancer cells. For example, cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis...
March 8, 2018: Blood
Ronan T Gray, Helen G Coleman, Carmel Hughes, Liam J Murray, Chris R Cardwell
BACKGROUND: Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC). Six observational studies have reported CRC-specific survival outcomes in patients using aspirin after CRC diagnosis but the results from these studies have been conflicting. Using a population-based cohort design this study aimed to assess if low-dose aspirin use after diagnosis reduced CRC-specific mortality. METHODS: A cohort of 8391 patients with Dukes' A-C CRC (2009-2012) was identified from the Scottish Cancer Registry and linked to national prescribing and death records...
February 27, 2018: BMC Cancer
Ariella De Monte, Davide Brunetti, Luigi Cattin, Francesca Lavanda, Erica Naibo, Maria Malagoli, Giorgio Stanta, Serena Bonin
Metformin, the drug of choice in the treatment of type 2 diabetes mellitus (DM2), in addition to aspirin (ASA), the drug prescribed for cardioprotection of diabetic and non-diabetic patients, have an inhibitory effect on cancer cell survival. The present population-based study conducted in the province of Trieste (Italy), aimed to investigate the prevalence of DM2 in patients with colorectal adenocarcinoma (CRC) and survival for CRC in diabetic and nondiabetic patients. All permanent residents diagnosed with a CRC between 2004 and 2007 were ascertained through the regional health information system...
March 2018: Molecular and Clinical Oncology
Claire Fan, Adam Younis, Christine E Bookhout, Seth D Crockett
PURPOSE OF REVIEW: The purpose of this review is to summarize the management of serrated colorectal polyps (SPs), with a particular focus on the most common premalignant SP, sessile serrated adenoma or polyp (SSA/P). These lesions present a challenge for endoscopists with respect to detection and resection, and are also susceptible to pathologic misdiagnosis. RECENT FINDINGS: Patients with SSA/Ps are at an increased risk of future colorectal neoplasia, including advanced polyps and cancer...
February 14, 2018: Current Treatment Options in Gastroenterology
Heike Gottschall, Christoph Schmoecker, Dirk Hartmann, Nadine Rohwer, Katharina Rund, Laura Kutzner, Fabian Nolte, Annika I Ostermann, Nils Helge Schebb, Karsten H Weylandt
Eicosanoids, including prostaglandins and thromboxanes, are broadly bioactive lipid mediators and increase colon tumorigenesis possibly through chronic inflammatory mechanisms. Epidemiological and experimental data suggest that acetylsalicylic acid (ASA) helps prevent colorectal cancer (CRC), possibly through cyclooxygenase (COX)-mediated suppression of eicosanoid - particularly prostaglandin E2 (PGE2) - formation. Recent studies suggest that statins prevent CRC and improve survival after diagnosis. We identified patients on ASA and/or statin treatment undergoing routine colonoscopy and measured eicosanoid levels in colonic mucosa with targeted metabolomics technology (LC-MS/MS)...
February 14, 2018: Journal of Lipid Research
Luis Bujanda, Cristina Sarasqueta, Pablo Vega, María Salve, Enrique Quintero, Victoria Alvarez-Sánchez, Fernando Fernández-Bañares, Jaume Boadas, Rafel Campo, Ana Garayoa, Angel Ferrandez, Leyanira Torrealba, Daniel Rodríguez-Alcaide, Mauro D'Amato, Vicent Hernández, Joaquin Cubiella
Background: Aspirin (ASA) is a drug that can cause gastrointestinal lesions and symptoms. Colorectal cancer (CRC) is the most prevalent type of cancer in Western countries. We assessed the effect of aspirin on the diagnostic accuracy of the faecal immunochemical test (FIT) for CRC and/or advanced neoplasia (AN) in patients undergoing colonoscopy for gastrointestinal symptoms. Methods: We conducted a prospective multicentre observational study of diagnostic tests that included patients with gastrointestinal symptoms undergoing colonoscopy between March 2012 and 2014 (the COLONPREDICT study)...
February 2018: United European Gastroenterology Journal
Harsh Sheth, Emma Northwood, Cornelia M Ulrich, Dominique Scherer, Faye Elliott, Jennifer H Barrett, David Forman, C Roland Wolf, Gillian Smith, Michael S Jackson, Mauro Santibanez-Koref, Robert Haile, Graham Casey, Mark Jenkins, Aung Ko Win, John L Hopper, Loic Le Marchand, Noralane M Lindor, Stephen N Thibodeau, John D Potter, John Burn, D Timothy Bishop
Regular aspirin use is associated with reduced risk of colorectal cancer (CRC). Variation in aspirin's chemoprevention efficacy has been attributed to the presence of single nucleotide polymorphisms (SNPs). We conducted a meta-analysis using two large population-based case-control datasets, the UK-Leeds Colorectal Cancer Study Group and the NIH-Colon Cancer Family Registry, having a combined total of 3325 cases and 2262 controls. The aim was to assess 42 candidate SNPs in 15 genes whose association with colorectal cancer risk was putatively modified by aspirin use, in the literature...
2018: PloS One
Pierre Michel, Valerie Boige, Thierry Andre, Thomas Aparicio, Jean Baptiste Bachet, Laetitia Dahan, Rosine Guimbaud, Côme Lepage, Sylvain Manfredi, David Tougeron, Julien Taieb, Janick Selves, Karine Le Malicot, Frederic Di Fiore, Emilie Maillard
Oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. Two recent retrospective studies strongly suggested that low-dose aspirin used (100 mg/d) after surgical resection of colorectal cancer with a PIK3CA mutation could act as a targeted therapy with a major protective effect on the risk of recurrence. We propose a double-blind randomized phase III study to evaluate aspirin (100 mg/d during 3 years or until recurrence) versus placebo...
December 30, 2017: Digestive and Liver Disease
Jun Ying, Hai-Yang Zhou, Peng Liu, Qing You, Fei Kuang, Yi-Nan Shen, Zhi-Qian Hu
Background: The metastasis of colorectal cancer frequently tends to liver, which is one of the three leading causes of cancer-related deaths worldwide. Growing evidence showed that aspirin could effectively inhibit liver metastasis of colorectal cancer. However, the potential mechanism has not been fully understood. Methods: Mouse splenic vein metastasis assay was used to examine the metastatic ability of colon cancer cells in vivo. And wound healing and transwell assay were applied to detect the metastasis potential of C26 and HCT116 colon cancer cell lines in vitro...
2018: Cell & Bioscience
Tomohiro Aoki, Shuh Narumiya
Background: Colorectal cancer is the third most common cancer. Involvement of prostaglandin (PG) system in the pathogenesis of colorectal cancer has been suggested from clinical studies demonstrating therapeutic effect of NSAIDs including aspirin or selective COX-2 inhibitors. However, mechanisms on how PG regulates inflammatory responses leading to colorectal cancer development remain obscure. Further, careful attention is needed to use these drugs for a long time because of adverse effects due to non-specific inhibition of physiological PG production in addition to pathological one, making the development of alternatives to aspirin important...
2017: Inflammation and Regeneration
L Yang, Z Lv, W Xia, W Zhang, Y Xin, H Yuan, Y Chen, X Hu, Y Lv, Q Xu, X Weng, C Ni
PURPOSE: Aspirin could reduce the risk of cancer metastasis. Circulating tumor cells (CTCs) are a key factor of cancer metastasis, but no evidence has revealed how aspirin affects CTCs and its epithelial-mesenchymal transition (EMT). Here, we conducted a clinical trial to investigate how aspirin affects CTCs in metastatic colorectal cancer (MCC) and breast cancer patients (MBC). METHODS: The trial is retrospective registered at (NCT02602938). The eligible patients are given 100 mg aspirin q...
December 14, 2017: Clinical & Translational Oncology
Magnus Løberg, Øyvind Holme, Mette Kalager
No abstract text is available yet for this article.
February 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Risa B Burns, Kelly Graham, Mandeep S Sawhney, Eileen E Reynolds
Aspirin exerts antiplatelet effects through irreversible inhibition of cyclooxygenase-1, whereas its anticancer effects may be due to inhibition of cyclooxygenase-2 and other pathways. In 2009, the U.S. Preventive Services Task Force endorsed aspirin for primary prevention of cardiovascular disease. However, aspirin's role in cancer prevention is still emerging, and no groups currently recommend its use for this purpose. To help physicians balance the benefits and harms of aspirin in primary disease prevention, the Task Force issued a guideline titled, "Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer" in 2016...
December 5, 2017: Annals of Internal Medicine
Hefei Wang, Bing Liu, Jing Wang, Jinglin Li, Ying Gong, Sisi Li, Chunli Wang, Bai Cui, Xiaoyuan Xue, Mengying Yang, Wenjun Fan, Zhijie Kang, Muhammad Kamran, Jie Xu, Pengfei Tian, Yuanyuan Luo, Zhijie Hou, Lin Dong, Yanling Ren, Man Li, Qingping Wen, Wei Cheng, Lingzhi Xu, Ling Wang, Quentin Liu
BACKGROUND/AIMS: Cancer stem cells (CSCs) are considered to be responsible for tumor relapse and metastasis, which serve as a potential therapeutic target for cancer. Aspirin has been shown to reduce cancer risk and mortality, particularly in colorectal cancer. However, the CSCs-suppressing effect of aspirin and its relevant mechanisms in colorectal cancer remain unclear. METHODS: CCK8 assay was employed to detect the cell viability. Sphere formation assay, colony formation assay, and ALDH1 assay were performed to identify the effects of aspirin on CSC properties...
2017: Cellular Physiology and Biochemistry
Adrien Grancher, Pierre Michel, Frédéric Di Fiore, David Sefrioui
Colorectal cancer is a worldwide public health problem. Aspirin has been identified as a protective factor against the apparition of colorectal cancer. There are several mechanisms about the actions by aspirin on colorectal tumorogenesis. These are not perfectly known nowadays. On one hand, there are direct mechanisms on colorectal mucosa, on the other hand there are indirect mechanisms through platelet functions. Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity...
November 15, 2017: Bulletin du Cancer
Mancang Gu, Reiko Nishihara, Yang Chen, Wanwan Li, Yan Shi, Yohei Masugi, Tsuyoshi Hamada, Keisuke Kosumi, Li Liu, Annacarolina da Silva, Jonathan A Nowak, Tyler Twombly, Chunxia Du, Hideo Koh, Wenbin Li, Jeffrey A Meyerhardt, Brian M Wolpin, Marios Giannakis, Andrew J Aguirre, Adam J Bass, David A Drew, Andrew T Chan, Charles S Fuchs, Zhi Rong Qian, Shuji Ogino
Evidence suggests that nonsteroidal anti-inflammatory drug aspirin (acetylsalicylic acid) may improve patient survival in PIK3CA-mutant colorectal carcinoma, but not in PIK3CA-wild-type carcinoma. However, whether aspirin directly influences the viability of PIK3CA-mutant colon cancer cells is poorly understood. We conducted in vitro experiments to test our hypothesis that the anti-proliferative activity of aspirin might be stronger for PIK3CA-mutant colon cancer cells than for PIK3CA-wild-type colon cancer cells...
October 20, 2017: Oncotarget
Sajesh K Veettil, Kean Ghee Lim, Siew Mooi Ching, Surasak Saokaew, Pochamana Phisalprapa, Nathorn Chaiyakunapruk
BACKGROUND: Beneficial effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) against recurrent colorectal adenomas have been documented in systematic reviews; however, the results have not been conclusive. Uncertainty remains about the appropriate dose of aspirin for adenoma prevention. The persistence of the protective effect of NSAIDs against recurrent adenomas after treatment cessation is yet to be established. METHODS: Our objective was to update and systematically evaluate the evidence for aspirin and other NSAIDs on the incidence of recurrent colorectal adenomas taking into consideration the risks of random error and to appraise the quality of evidence using GRADE (The Grading of Recommendations, Assessment, Development and Evaluation) approach...
November 14, 2017: BMC Cancer
Elsa N Garza-Trevino, Martha S Rodriguez-Gonzalez, Paulina Delgado Gonzalez, Yesenia G Alonso-Cruz, Yesenia G Alonso-Cruz, Adolfo Soto-Dominguez, Juan F Gonzalez Guerrero, Yanko Castro-Govea, Emiliano Michel Sanchez, Salvador Said Fernandez, Herminia G Martinez-Rodriguez
PURPOSE: To determine in vitro, the efficacy and safety window of not-front-line and first-line anti-colorectal (CRC) drug combinations. METHODS: The adenocarcinoma cell line Colo 320DM and normal human mesenchymal stem cells derived from adipose tissue were used respectively to determine the anti-CRC efficacy (% of Colo 320DM cell death [CD]) and safety window [SW] - % Colo 320DM percent cancer death (PCD)/% of mesenchymal stem cell's death) of drug combinations, using the adenosine triphosphate-based chemotherapy response assay (ATP-CRA)...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
Tsuyoshi Takiuchi, Erin A Blake, Koji Matsuo, Anil K Sood, Theodore M Brasky
The role of acetylsalicylic acid (aspirin) as a chemo-preventive and adjuvant therapeutic agent for cancers is generating attention. Mounting evidence indicates that aspirin reduces the incidence and mortality of certain obesity-related cancers, particularly colorectal cancer. In endometrial cancer, previous studies examining the effect of aspirin remain inconsistent as to the reduction in the risk of endometrial cancer. While some evidence indicates protective effects in obese women, other studies have showed a potential deleterious effect of these medications on endometrial cancer outcomes...
November 10, 2017: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"